TrialGynecologic oncology2019

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.

Roisin E O'Cearbhaill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.